News

The potential for innovative gene therapies to treat and even cure a range of serious diseases is prompting FDA to ramp up support for developing and testing new products efficiently and effectively.

Given the rapid changes in the communication landscape brought about by participative Internet use and social media, it is important to develop a better understanding of these technologies and their impact on health communication.

Patients stand to lose the most when sponsors hold too tightly to drugs doomed to fail. This wastes precious time that patients don’t have and squanders valuable resources.

// You can adjust the form size here: var DrupalLeadsFormWidth = 870; var DrupalLeadsFormHeight = 2500;

Exploring that pivotal question for clinical investigators, sponsors, and global CROs.

FDA is testing various strategies to streamline research and regulatory oversight by looking to novel clinical trial designs to advance new treatments.

Although Biogen's Alzheimer's drug BAN2401 addresses buildup of amyloid plaques, investors and scientists look to reevaluate the plaque theory and search for a glimmer of hope in breakthrough treatments.

The Business Research Company publishes a report that the global market for clinical trial services to biopharmaceutical and medical device companies is forecast to grow at 12% year-on-year to 2021.

A continued struggle for healthcare and healthcare innovation to be taken seriously by the EU.

Switching from paper records to an electronic drug accountability IRT system can benefit sites during FDA trial site audits.

Assessing the benefits of using blockchain technology as a notary service in the network sharing of clinical data.

Analyzing data to reveal site performance patterns for better trial planning and execution.

Click the title above to open the Applied Clinical Trials July/August 2018 issue in an interactive PDF format.